Mereo BioPharma Group (MREO) Analyst & Key Data

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

5

Hold

2

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score4.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$0.28

Median Target+660.71%

$2.13

Potential upside vs current price

DCF Value-5.99%

$0.26

Potential downside vs current price

Current Stock Price

$0.28

Median Target+660.71%

$2.13

Potential upside vs current price

DCF Value-5.99%

$0.26

Potential downside vs current price

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

5

Hold

2

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score4.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$0.28

Median Target+660.71%

$2.13

Potential upside vs current price

DCF Value-5.99%

$0.26

Potential downside vs current price

Current Stock Price

$0.28

Median Target+660.71%

$2.13

Potential upside vs current price

DCF Value-5.99%

$0.26

Potential downside vs current price

Mereo BioPharma Group plc